The RASopathies

By K. Rauen. Annual review of genomics and human genetics (Print), 2013

758 citations recorded by the source corpus.

The RASopathies are a clinically defined group of medical genetic syndromes caused by germline mutations in genes that encode components or regulators of the Ras/mitogen-activated protein kinase (MAPK) pathway. These disorders include neurofibromatosis type 1, Noonan syndrome, Noonan syndrome with multiple lentigines, capillary malformation–arteriovenous malformation syndrome, Costello syndrome, cardio-facio-cutaneous syndrome, and Legius syndrome. Because of the common underlying Ras/MAPK pathway dysregulation, the RASopathies exhibit numerous overlapping phenotypic features. The Ras/MAPK pathway plays an essential role in regulating the cell cycle and cellular growth, differentiation, and senescence, all of which are critical to normal development. Therefore, it is not surprising that Ras/MAPK pathway dysregulation has profound deleterious effects on both embryonic and later stages of development. The Ras/MAPK pathway has been well studied in cancer and is an attractive target for small-molecule inhibition to treat various malignancies. The use of these molecules to ameliorate developmental defects in the RASopathies is under consideration.

Subfields: Molecular Biology, Neurology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/dc9e47829c1cba5692073eb5c21b082423fe7271

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

S. Huson
R. Ferner
E. Legius
D. Evans
L. Messiaen
D. Gutmann
B. Korf
P. Wolkenstein

Citations in the corpus

Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation (2021, background): “NF1 was the first human condition mapped to the RAS pathway but subsequently other conditions have been shown to be caused by pathogenic variants (PVs) in RAS pathway genes, including Noonan, Costello, and cardiofaciocutaneous syndromes.(12) Together, this group of conditions is referred to as RASop”